RADICAVA ORS® (edaravone) is an ORAL administration option of RADICAVA® (edaravone), an ALS treatment shown to slow the loss of physical function.
TO LEARN MORE ABOUT RADICAVA®, SPEAK WITH A JOURNEYMATE RESOURCE SPECIALIST 1-855-457-6968. SEE MORE
TO LEARN MORE ABOUT RADICAVA®, SPEAK WITH A JOURNEYMATE RESOURCE SPECIALIST 1-855-457-6968. SEE MORE
FDA-APPROVED & AVAILABLE
For Your Moments Big and Small
Actor portrayals.
How Treatment Can Help
RADICAVA® has been shown to slow physical function loss by 33% (approximately one-third) vs placebo.
Taking Treatment Orally
RADICAVA ORS® 5 mL dose may take only a few minutes to administer on treatment days. a,b (see footnote)
Getting Started
RADICAVA® has been used by 8000+ patients.c (see footnote) See how to start RADICAVA ORS® or switch from RADICAVA® IV.
A patient-focused approach for ALS and treatment support
No matter where you are in your ALS journey—from diagnosis to treatment—the JourneyMate Support Program™ gives you the understanding, answers, and resources to help you move forward.
If you're new to treatment, the program can help you learn more about RADICAVA®. If you're currently using RADICAVA® IV, the program can help you learn more about switching to RADICAVA ORS®.
The RADICAVA® Educational Communications Series—Sign Up Today
Join our community of 11,500+ people who’ve signed up to learn more about RADICAVA ORS® or RADICAVA® IV and why it matters to patients and caregivers.
Help other people living with ALS by sharing your experience with ALS and RADICAVA®. See how you can share
ALS=amyotrophic lateral sclerosis; IV=intravenous.
aThe initial treatment cycle starts with daily dosing of RADICAVA ORS® for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles include daily dosing 10 out of 14 days followed by a 14-day drug-free period. Return to content
bUse the provided 5 mL syringe that comes with the product. Do not use a household teaspoon to measure your medication. Return to content
cBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of September 2022. Not independently verified. Return to content.
